Mylan’s sudden plans for a generic EpiPen image

Modern Healthcare, Vital Signs Blog, August 31, 2016
Adam Rubenfire, quoting Rachel E. Sachs (Academic Fellow alumna)


Read the Full Article

From the post:

Obviously Mylan didn't want to underprice its own branded drug, but it's possible they had filed away plans for a generic version in case a significant competitor arose. Rachel Sachs, an associate professor at Washington University School of Law in St. Louis, points out that Mylan likely drew up generic plans to rival Israel-based Teva Pharmaceutical Industries, which has faced difficulty in gaining approval for a generic epinephrine auto-injector. 

“It may well have been on the list of things they were considering, especially when it looked like Teva was going to get approval,” said Sachs, a health law expert. “They probably had some amount of that ready to go, only now in a week of intense media scrutiny did they actually complete that step.” 

bioethics biotechnology fda health care finance health care reform health law policy pharmaceuticals rachel sachs regulation